登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C14H10Cl2NNaO2
化学文摘社编号:
分子量:
318.13
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
grade
pharmaceutical primary standard
API family
diclofenac
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
[Na+].[O-]C(=O)Cc1ccccc1Nc2c(Cl)cccc2Cl
InChI
1S/C14H11Cl2NO2.Na/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19;/h1-7,17H,8H2,(H,18,19);/q;+1/p-1
InChI key
KPHWPUGNDIVLNH-UHFFFAOYSA-M
Gene Information
human ... PTGS1(5742), PTGS2(5743)
General description
双氯芬酸钠是一种非甾体抗炎药（NSAID）双氯芬酸的钠盐。它通过抑制环氧合酶活性来防止与疼痛、炎症和发烧有关的前列腺素的合成。
本品按现行药典规定交付。所有为支持本产品而提供的信息，包括SDS和任何产品信息单均由药典颁发机构制定并发布。如需进一步信息和支持，请访问现行药典网站。
Application
双氯芬酸钠USP 参考标准品适用于指定USP 药典质量测试和分析。
还用于制备酸级标准（acid stage standard）、标准、标准储备、敏感性和系统适用性溶液，用于根据美国药典 (USP) 的以下专论，通过液相色谱和紫外检测器进行检测、杂质分析、鉴定和性能测试：
还用于制备酸级标准（acid stage standard）、标准、标准储备、敏感性和系统适用性溶液，用于根据美国药典 (USP) 的以下专论，通过液相色谱和紫外检测器进行检测、杂质分析、鉴定和性能测试：
- 双氯芬酸钠
- 双氯芬酸钠延迟释放片
- 双氯芬酸钠缓释片
- 双氯芬酸钠外用溶液
- 双氯芬酸钠和迷索前列醇延迟释放片
Biochem/physiol Actions
标准NSAID和环加氧酶（COX）抑制剂。主要代谢物是4′-羟基二苯甲酸和5′-羟基二氯芬酸。已被用作CYP2C9的选择性底物。
Analysis Note
这些产品仅供测试和分析使用。它们不适用于人类或动物的给药，不可用于诊断、治疗或治愈任何疾病。
Other Notes
可能适用相应的销售限制。
Still not finding the right product?
Explore all of our products under 双氯芬酸钠
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral - Aquatic Chronic 2 - Repr. 2 - STOT RE 1
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
flash_point_f
Not applicable
flash_point_c
Not applicable
D Aygün et al.
Histology and histopathology, 27(4), 417-436 (2012-03-01)
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for the purpose of anti-inflammation, antipyretic, and analgesia. For this aim, they are used for the alleviation of pain, fever, and inflammation associated with rheumatoid arthritis, sports injuries, and temporary pain. However, treatment
Paul L McCormack et al.
Drugs, 68(1), 123-130 (2007-12-18)
*A new formulation of the nonselective NSAID diclofenac sodium suitable for intravenous bolus injection has been developed using hydroxypropyl beta-cyclodextrin as a solubility enhancer (HPbetaCD diclofenac). * HPbetaCD diclofenac intravenous bolus injection was shown to be bioequivalent to the existing
R E Small
Clinical pharmacy, 8(8), 545-558 (1989-08-01)
The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage of diclofenac sodium are reviewed. Diclofenac, the first nonsteroidal anti-inflammatory agent (NSAID) to be approved that is a phenylacetic acid derivative, competes with arachidonic acid for binding to cyclo-oxygenase, resulting in
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 1188800-200MG | 04061838708304 |